Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites--current status.
The status of the radiochemical development and biological evaluation of radioligands for PET studies of central benzodiazepine (BZ) receptors and the so-called peripheral benzodiazepine binding sites, here discriminated and referred to as PK binding sites, is reviewed against current pharmacological knowledge, indicating those agents with present value and those with future potential. Practical recommendations are given for the preparation of two useful radioligands for PET studies, [N-methyl-11C]flumazenil for central BZ receptors, and [N-methyl-11C]PK 11195 for PK binding sites. Quality assurance and plasma metabolite analysis are also reviewed for these radioligands and practical recommendations are given on methodology for their performance.
MRC Cyclotron Unit, Hammersmith Hospital, London, England.
V W
VW
Pike
C
C
Halldin
C
C
Crouzel
L
L
Barré
D J
DJ
Nutt
S
S
Osman
F
F
Shah
D R
DR
Turton
S L
SL
Waters
D000818:Animals; D001569:Benzodiazepines / Q000378:metabolism; D001665:Binding Sites; D002250:Carbon Radioisotopes; D005442:Flumazenil; D005462:Fluorine Radioisotopes; D006801:Humans; D007546:Isoquinolines; D008024:Ligands; D011868:Radioisotopes; D011869:Radioligand Assay; D011963:Receptors, GABA-A / Q000032:analysis*; D014055:Tomography, Emission-Computed
D002250:Carbon Radioisotopes; D005462:Fluorine Radioisotopes; D007546:Isoquinolines; D008024:Ligands; D011868:Radioisotopes; D011963:Receptors, GABA-A; D001569:Benzodiazepines; D005442:Flumazenil; C037850:PK 11195